The FDA has classified as Class II an ongoing recall of bulk active pharmaceutical ingredient supplied by Shoolin Pharma Chem LLP — sildenafil citrate USP and tadalafil USP in 100 g, 500 g and 1 kg bags, all labelled 'for prescription compounding only'. The stated reason is deviation from current good manufacturing practice, noted during an FDA inspection. The classification was posted on 19 August 2026.
Read the scope carefully, because this is the part that gets garbled. The recall covers raw drug substance sold to compounding pharmacies, not finished proprietary or generic tablets. A man taking a licensed sildenafil or tadalafil product is not affected by it. What is affected is any compounded preparation — troches, dissolvable films, combination compounds, liquid formulations for men who cannot swallow tablets — made from this supplier's material.
Class II means exposure may cause temporary or medically reversible harm with serious injury unlikely, and a good manufacturing practice deviation found at inspection is a statement about process control rather than about a specific defect in the product. It is nonetheless a reasonable prompt to ask, of any patient using a compounded phosphodiesterase-5 inhibitor, where it was made — a question worth asking regardless of this recall, given how much unlicensed material circulates in this therapeutic area. The record concerns a US enforcement action and does not address supply in any other country, and the CDSCO position on this material is not stated in it.
- Reassure patients on licensed sildenafil or tadalafil tablets — finished products are not covered.
- Ask any patient using a compounded PDE5 preparation where it was compounded and from whose material.
- Class II describes a process deviation found at inspection, not a specific defect in a dose.
- Treat this as a reason to prefer licensed finished products where a compounded formulation is not clinically necessary.
- The record covers US distribution and says nothing about supply elsewhere.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free